Carisma Therapeutics On June 26, Notified Novartis Pharmaceuticals Of Termination Of Co's Manufacturing & Supply Agreement Between Co & Novartis

Reuters
2024.07.02 21:01
portai
I'm PortAI, I can summarize articles.

Carisma Therapeutics has terminated its manufacturing and supply agreement with Novartis Pharmaceuticals, effective July 31, 2024. The company will now focus on its follow-on product candidate CT-0525 for ex vivo oncology clinical development. Enrollment of new patients in its phase 1 clinical trial for CT-0508 has been suspended.

July 2 (Reuters) - Carisma Therapeutics Inc (CARM.O) :

  • CARISMA THERAPEUTICS : ON JUNE 26, NOTIFIED NOVARTIS PHARMACEUTICALS OF TERMINATION OF CO’S MANUFACTURING & SUPPLY AGREEMENT BETWEEN CO & NOVARTIS

  • CARISMA THERAPEUTICS INC - TERMINATION OF CO’S MANUFACTURING AND SUPPLY AGREEMENT, BY AND BETWEEN CO AND NOVARTIS IS EFFECTIVE JULY 31, 2024

  • CARISMA THERAPEUTICS - CO DETERMINED TO FOCUS EX VIVO ONCOLOGY CLINICAL DEVELOPMENT EFFORTS ON ITS FOLLOW-ON PRODUCT CANDIDATE CT-0525

  • CARISMA THERAPEUTICS INC - HAS SUSPENDED ENROLLMENT OF NEW PATIENTS IN ITS PHASE 1 CLINICAL TRIAL FOR CT-0508

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.